Monitoring late-onset toxicities in phase I trials using predicted risks
about
Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).Advances in Statistical Approaches Oncology Drug Development.Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.Risk-group-specific dose finding based on an average toxicity score.The rapid enrollment design for Phase I clinical trials.Dose escalation methods in phase I cancer clinical trials.Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology TrialsBayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity.A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.Nonparametric overdose control with late-onset toxicity in phase I clinical trials.A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy.
P2860
Q30868533-0AA65B54-A178-4012-B7DD-7C4AA738D5B9Q34001009-9A2553C3-3410-4D3E-8F1A-8CC04FF0116DQ34799578-F6770A3B-BAFA-4D57-96EE-B7D292F194B6Q35565672-B7DC3BDB-8A20-42E5-B3B3-74D385777404Q36033877-363352C0-CFA1-4055-A14D-F286C4BF1124Q36062118-D92D2024-E224-4698-B4C7-E48C5999AEE4Q36968447-AD1AFF0D-5185-46DF-A726-0DA782078884Q37198192-378E5BE1-5011-4A6D-896D-8062FDF739BBQ37523183-FFCA6435-A45C-45DC-8FE7-23FC33B25B4FQ37841138-68371B91-5D6E-4771-95A6-C2D95507016BQ38428895-92647A2D-47DC-4BE3-848E-078F4194C8D3Q38735952-BE3E891F-4128-4BE9-B01D-EBD470A6B469Q40525726-AEA77FF1-DD51-4D61-BEF4-410CFF50E728Q40543401-4AABC145-A5FA-4367-8FB6-72116C480CCDQ42113412-D6530D17-C4BF-4E09-B71B-E56DE820AA2EQ42664108-74BF2504-0FD5-40CA-AF10-8F592ABCF846Q50593013-841AF0D6-B30E-45E0-8A71-2102061E20E0Q51105513-D7F349A3-9970-47AE-8BF0-EE15E9025ED4
P2860
Monitoring late-onset toxicities in phase I trials using predicted risks
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Monitoring late-onset toxicities in phase I trials using predicted risks
@ast
Monitoring late-onset toxicities in phase I trials using predicted risks
@en
type
label
Monitoring late-onset toxicities in phase I trials using predicted risks
@ast
Monitoring late-onset toxicities in phase I trials using predicted risks
@en
prefLabel
Monitoring late-onset toxicities in phase I trials using predicted risks
@ast
Monitoring late-onset toxicities in phase I trials using predicted risks
@en
P2093
P2860
P356
P1433
P1476
Monitoring late-onset toxicities in phase I trials using predicted risks
@en
P2093
B Nebiyou Bekele
Peter F Thall
P2860
P304
P356
10.1093/BIOSTATISTICS/KXM044
P577
2007-12-14T00:00:00Z